Pharmaceuticals Japan

Japan Postpartum Depression Treatment Market Analysis, 2024–2034

Updated Reviewed by Vidhi Upadhyay

Japan Postpartum Depression Treatment Market Industry Trends and Forecast to 2034: Segmented by (Treatment, Drug, End User, Region) - Growth, Market Size, Future Prospects & Competitive Analysis, 2024-2034

Overview

Market Dashboard

Japan · 2024–2034 · placeholder estimates

Values shown here are placeholder estimates, not researched figures. Researched 2024 historical, 2025 base-year and 2026–2034 forecast values are prepared with the full report.

Estimate 2024 $43.7 Mn Placeholder estimate
Estimate 2025 $49.7 Mn 6.5% of the global market
Projected 2034 $159.2 Mn 220.1% Adds $109.5 Mn over 9 forecast years
CAGR 2025–2034 13.8% Faster than 72% of 180 Pharmaceuticals markets here
Key players 5
  • Japan is 6.49% of the global market.
  • In APAC, the largest is China at $72.1 Mn.
  • Fastest growing: India at 16% a year.
  • Japan ranks 2nd of 10 by size in APAC.

Market size projection

Japan

Source: Acuitas Health Analytics. Full methods, sources and usage terms come with report purchase.

Value added each year

$109.5 Mn total, 2026–2034

Year-by-year market size, 2024–2034
Postpartum Depression Treatment Market market size by year, Japan
YearMarket sizeChange that yearSince 2025
2024 (estimate) $43.7 Mn — —
2025 (base) $49.7 Mn +$6.0 Mn —
2026 (forecast) $56.6 Mn +$6.9 Mn +13.8%
2027 (forecast) $64.4 Mn +$7.8 Mn +29.5%
2028 (forecast) $73.3 Mn +$8.9 Mn +47.4%
2029 (forecast) $83.4 Mn +$10.1 Mn +67.7%
2030 (forecast) $94.9 Mn +$11.5 Mn +90.9%
2031 (forecast) $108.0 Mn +$13.1 Mn +117.2%
2032 (forecast) $122.9 Mn +$14.9 Mn +147.2%
2033 (forecast) $139.9 Mn +$17.0 Mn +181.3%
2034 (forecast) $159.2 Mn +$19.3 Mn +220.1%

Placeholder estimates. Each year is projected from our earlier market estimate and its CAGR. Researched values come with the full report.

Same market worldwide

By geography

  1. Global $766.1 Mn
  2. North America $333.6 Mn
  3. US $288.5 Mn
  4. APAC $183.9 Mn
  5. Europe $146.5 Mn
  6. China $72.1 Mn
  7. Canada $68.7 Mn
  8. Japan (this report) $49.7 Mn
  9. Latin America $33.1 Mn
  10. Middle East $31.0 Mn
  11. Germany $27.9 Mn
  12. France $23.4 Mn
  13. Brazil $19.4 Mn
  14. UK $17.4 Mn
  15. Ecuador $17.4 Mn
  16. Italy $17.0 Mn
  17. Spain $15.7 Mn
  18. India $13.9 Mn
  19. Africa $12.7 Mn
  20. Saudi Arabia $12.3 Mn
  21. Mexico $10.1 Mn
  22. Russia $8.4 Mn
  23. Australia $8.4 Mn
  24. New Zealand $7.7 Mn
  25. South Africa $5.6 Mn
  26. UAE $4.0 Mn
  27. Egypt $2.2 Mn
  28. Philippines $1.7 Mn
  29. Hong Kong $1.3 Mn
  30. Malaysia $1.2 Mn
  31. Thailand $0.9 Mn
  32. Singapore $0.8 Mn
  33. Kenya $0.7 Mn

Report snapshot

Japan Postpartum Depression Treatment Market Analysis at a glance
Market size, 2025$49.7 Mn placeholder estimate
Forecast, 2034$159.2 Mn placeholder estimate
Growth (CAGR), 2025–203413.8% placeholder estimate
Years2024 historical · 2025 base year · 2026–2034 forecast
Also calledPostpartum Depression Drugs
SegmentsTreatment, drug and end user (see all)
Key playersSage Therapeutics, Biogen Inc, Pfizer Inc., Lundbeck, Eli Lilly and Company (see all)
Regulator in JapanPMDASource: Pharmaceuticals and Medical Devices Agency. Checked 14 Nov 2026.
FormatsPDF, PPTX, XLSX

Sizes and growth here are placeholder estimates, not researched figures. Researched figures come with the full report.

The Japan Postpartum Depression Treatment Market Analysis Executive Summary

Postpartum depression treatment helps new mothers with depression after childbirth, using new rapid-acting medicines, antidepressants and therapy.

Key segments of the postpartum Depression Treatment market include treatment (Neuroactive Steroids, Antidepressants and Psychotherapy) and drug (Zuranolone, Brexanolone and SSRIs).

Bar chart: Japan Postpartum Depression Treatment market size, 2024–2034, placeholder estimates. $43.7 Mn in 2024, $49.7 Mn in 2025 and $159.2 Mn in 2034, 13.8% CAGR.
Japan Postpartum Depression Treatment market size, 2024–2034. Placeholder estimates; researched figures come with the full report. Source: Acuitas Health Analytics.

Japan Postpartum Depression Treatment Market Dynamics

Market Growth Drivers

Greater awareness of women's health needs, more funding for female-focused research, later pregnancies and an ageing female population are driving the postpartum Depression Treatment market. New products designed around women's biology and digital care are improving access.

Opportunity

Femtech, personalised care and new treatments for under-served conditions open strong growth for the postpartum Depression Treatment market, especially as employers and payers add women's health benefits.

Market Restraints

Under-diagnosis, stigma around some conditions, limited insurance coverage and a long history of under-research in women's health hold back the postpartum Depression Treatment market.

Competitive Landscape for Postpartum Depression Treatment Market in Japan

The postpartum Depression Treatment market is moderately concentrated. Leading companies compete on product innovation, clinical evidence, pricing and geographic reach, and use partnerships and acquisitions to expand their portfolios.

Key Players

Healthcare Policies and Regulatory Landscape for Postpartum Depression Treatment Market in Japan

Postpartum Depression Treatment in Japan: rules and payment

Drugs are reviewed by the Pharmaceuticals and Medical Devices Agency (PMDA) and approved by the Ministry of Health, Labour and Welfare (MHLW).⁠[1] Everyone is covered by public health insurance, and the Ministry of Health, Labour and Welfare sets the official price list for covered medicines (NHI prices).⁠[2]

[1] Pharmaceuticals and Medical Devices Agency. Checked 14 Nov 2026.

[2] Ministry of Health, Labour and Welfare. Checked 14 Nov 2026.

Policy changes and Reimbursement scenario

Regulators such as the US FDA, the European Medicines Agency and national drug authorities set approval, pricing and safety rules for postpartum Depression Treatment. Reimbursement decisions by public payers and insurers shape how fast new therapies reach patients in Japan.

Beyond the market numbers

Research, trials and patients

What doctors and scientists are doing in Postpartum Depression Treatment right now, from free public sources.

Latest research 1,194 papers since 2021 (worldwide)

  1. Disruption of the Non-classical ERα-PCYT1A-Phospholipid-NR5A2 Axis impairs kisspeptin signaling in hypothalamic KNDy neurons and drives postpartum depression. Translational psychiatry, 2026
  2. Women's mental health in Saudi Arabia: gender gaps, barriers to care, and a culturally integrated framework. Frontiers in psychology, 2026
  3. Bilirubin in depression: redox-inflammatory mechanisms, clinical associations, and biomarker potential. Neuroscience, 2026
  4. Postpartum Depression - From Evolutionary Concepts to Neuropsychoendocrinological Backgrounds and New Treatment Medications. Alpha psychiatry, 2026
  5. Evolving treatment approaches for postpartum depression: The role of neuroactive steroids. The Nurse practitioner, 2026
Search all of them on PubMed (opens in a new tab)

Sources: PubMed (US National Library of Medicine), ClinicalTrials.gov, World Bank. Fetched 12 Nov 2026. Papers and trials are found by search words, so the counts are a guide. Titles only; read each paper at its source.

Public data, with sources

Postpartum Depression Treatment in context

Japan compared

  • Health spending per person: 3,638 US$ per person (2023). World: 1,317 US$ per person (2023). 4th highest of the 15 countries we cover in APAC.[1]
  • Doctors: 2.65 per 1,000 people (2022). World: 1.86 per 1,000 people (2022). 5th highest of the 15 countries we cover in APAC.[2]
  • People aged 65 and over: 30.0% of people (2025). World: 10.4% of people (2025). Highest of the 16 countries we cover in APAC.[3]

[1] World Bank Open Data, Health spending per person (US$ per person). Retrieved 15 Nov 2026.

[2] World Bank Open Data, Doctors (per 1,000 people). Retrieved 14 Nov 2026.

[3] World Bank Open Data, People aged 65 and over (% of people). Retrieved 15 Nov 2026.

Free data on this topic

Quick answers

Frequently asked questions

How big is the Postpartum Depression Treatment market in Japan?
Placeholder estimate: about $49.7 Mn in 2025, rising to about $159.2 Mn by 2034. These are early estimates, not researched figures; the researched values come with the full report.
How fast is the Postpartum Depression Treatment market in Japan growing?
Placeholder estimate: about 13.8% a year (CAGR, 2025–2034). The researched growth rate comes with the full report.
What segments does the Postpartum Depression Treatment market report cover?
The report splits the market by treatment (Neuroactive Steroids, Antidepressants, Psychotherapy, Digital Therapy), drug (Zuranolone, Brexanolone, SSRIs) and end user (Hospitals, Specialty Clinics, Retail Pharmacies, Online Pharmacies).
Who are the key players in the Postpartum Depression Treatment market?
Key players include Sage Therapeutics, Biogen Inc, Pfizer Inc., Lundbeck and Eli Lilly and Company.
What is driving the Postpartum Depression Treatment market?
Greater awareness of women's health needs, more funding for female-focused research, later pregnancies and an ageing female population are driving the postpartum Depression Treatment market. New products designed around women's biology and digital care are improving access.
Who regulates Postpartum Depression Treatment in Japan?
Drugs are reviewed by the Pharmaceuticals and Medical Devices Agency (PMDA) and approved by the Ministry of Health, Labour and Welfare (MHLW). Source: Pharmaceuticals and Medical Devices Agency. Checked 14 Nov 2026.
How is healthcare paid for in Japan?
Everyone is covered by public health insurance, and the Ministry of Health, Labour and Welfare sets the official price list for covered medicines (NHI prices). Source: Ministry of Health, Labour and Welfare. Checked 14 Nov 2026.
How much research is published on Postpartum Depression Treatment?
PubMed lists 1,194 papers on Postpartum Depression Treatment added since January 2021, worldwide. Source: PubMed, Papers added since 1 January 2021 matching this market. Retrieved 12 Nov 2026.
Get a free sample The table of contents and sample pages. No payment needed. Request sample Consult Us Questions about Postpartum Depression Treatment in Japan? Our analysts can size it for your plan. Talk to us See the public data Health figures for every country, free. Open the Public Health Dashboard

From our blog

Adaptogens: Ancient Herbs, Modern Market170 WHO Member States report the use of traditional medicine. Adaptogens like ashwagandha, rhodiola and… Stress and Mood Supplements: Ashwagandha and BeyondDepression and anxiety cost the world about US$1 trillion a year. Ashwagandha has some evidence for stress… Women's Health Supplements: A Growing FocusAnaemia affects about half a billion women worldwide, and folic acid before pregnancy prevents serious birth…
Back to Catalogue
Keep exploring

Related Pharmaceuticals reports in Japan

See all
Same topic, other categories

Related on mental health and maternal

See the topic